Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Hepatitis C is one of the most common causes of long-term liver disease in the United States.
Ribavirin and peginterferon alfa-2a are two medications that are used to treat hepatitis C
infection. The purpose of this study is to evaluate the safety of these two medications in
adults with hepatitis C and thalassemia, a type of blood disorder.